Methylnaltrexone as a method to imprOVE platelet inhibition of ticagrelor in morphine-treated patients with ST-segMENT elevation myocardial infarction: a prospective, single blinded, randomized, placebo-controlled Trial - MOVEMENT - trial

Karolinska Institutet0 个研究点开始时间: 2015年9月8日最近更新: 2016年4月11日

适应症

试验速览

暂无简介。

•Diagnosis of STEMI: Presence of typical symptoms, e.g. chest pain for more than 15 minutes together with new ST-segment elevation (>1mm [0.1mV] in two adjoining limb or chest leads, >2mm [0.2mV] in V2 and V3 for men, or >1,5mm [1.5mV] in V2 and V3 for women) in the absence of left ventricular hypertrophy or left branch bundle block (LBBB) on 12-lead ECG; 2)
•180 mg loading dose ticagrelor has been given before initiation of coronary angiography
•Analgesic treatment with intravenous morphine has been administered before initiation of coronary angiography
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 40

•Cardiac arrest
•Inability to understand study outline and instructions
•Methylnaltrexone bromide contraindication, including
•oKnown hypersensitivity to the active substance or to any of the excipients:
•-Sodium chloride
•-Sodium calcium edetate
•-Glycine hydrochloride
•-Water for injections
•-Hydrochloric acid (to adjust pH)
•-Sodium hydroxide (to adjust pH
•-Known or suspected mechanical gastro-intestinal obstruction or other acute surgical abdominal conditions
•Age <18 years
•Women in fertile age
•Administration of ticagrelor within 7 days before onset of STEMI symptoms

发起方